BRCA2 and neoplasm: Second, tumor-only sequencing was performed, and it was difficult to differentiate somatic mutations from those with germline origin, which might hinder the clinical applicability, particularly for PARP inhibitors, as germline mutation of BRCA1 or BRCA2 is the prerequisite for synthetic lethality.